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Abstract
Aims This bioequivalence study aimed to compare rate and
extent of absorption of a generic medicinal product of
ibandronic acid 150-mg film-coated tablet versus Bonviva.
Methods This was a single-centre, open-label, random-
ized, three-way, three-sequence, reference-replicated,
crossover bioequivalence study, under fasting conditions.
A single oral dose of ibandronic acid as one 150-mg film-
coated tablet was administered in each study period. Each
washout period lasted 14 days. Blood samples were col-
lected according to a predefined sampling schedule and up
to 48.0 hours after administraton in each period. Plasma
concentrations of ibandronic acid were measured using a
liquid chromatograph–mass spectrometry/mass spectrom-
etry method. Bioequivalence between generic and refer-
ence medicinal products is acceptable if the 90 %
confidence intervals (CI) of ratio of least-squares means
between the test and the reference product of ln-trans-
formed area under the serum concentration–time curve
from time zero to time of last measurable concentration
(AUC0–t) is within the 80.00–125.00 % interval. Prospec-
tively, a scaled average bioequivalence approach for
maximum serum concentration (Cmax) was established.
Results 153 healthy volunteers were enrolled and ran-
domized. After the test formulation (T) and first and second
Bonviva (R) dosing, the Cmax was 96.71 ± 90.19 ng/mL,
92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the
AUC0–t was 390.83 ± 287.27 ngh/mL, 388.54 ± 356.76
ngh/mL and 383.53 ± 246.72, respectively. Ratios of T/R
and 90 % CI were 100.92 % (94.35–107.94) for AUC0–t,
100.90 % (94.37–107.88) for AUC0–inf and 102.56 %
(95.05–110.67) for Cmax.
Conclusions Test formulation of ibandronic acid is bio-
equivalent in rate and extent of absorption to Bonviva
following a 150-mg dose, under fasting conditions.




pane-1,1-diyl}bis(phosphonic acid) is a nitrogen-contain-
ing bisphosphonate (ATC M05BA06; CAS 114084-78-5)
acting as an inhibitor of osteoclast-mediated bone resorp-
tion. Ibandronic acid is effective for the treatment and
prevention of osteoporosis in postmenopausal women with
increased risk of fractures, and a reduction in the risk of
vertebral fractures has been demonstrated [1].
The absorption of ibandronic acid in the upper gastro-
intestinal tract is rapid after oral administration. In fasted
state, the maximum observed plasma concentration (Cmax)
is reached within 0.5–2 hours (median 1 hour). The oral
bioavailability after oral administration is low (*0.6 %)
and highly variable. Bioavailability is reduced by 90 % in
the presence of a standard breakfast and by approximately
75 and 30 % when is administered 2 hours after a standard
meal and 30 minutes before a meal, respectively. There is
no meaningful reduction in bioavailability provided
ibandronic acid is taken 60 minutes before a meal [1, 2].
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There is no evidence of dose-dependent pharmacoki-
netics in the range of 2.5–50 mg oral dosage. The exposure
following administration of 50, 100 or 150 mg was not
dose proportional, with area under the serum concentra-
tion–time curve (AUC) and Cmax presenting greater
increase in exposure with increasing dose. The reason for
these dose-dependent pharmacokinetics is not fully eluci-
dated [1, 2].
In humans, the apparent terminal volume of distribu-
tion is high (*90 L), which is most likely related to
substantial distribution within skeletal tissue: the amount
of dose removed from the circulation via the bone is
estimated to be 40–50 % and the remainder is eliminated
unchanged by the kidney. The unabsorbed fraction of
ibandronic acid is eliminated unchanged in the faeces.
Protein binding in human plasma is approximately 87 %
at therapeutic concentrations, and drug–drug interaction
due to displacement is unlikely. There is no evidence that
ibandronic acid is metabolized in animals or humans. The
observed apparent elimination half-life (T el) for iband-
ronic acid is generally in the range of 10–72 hours. Total
clearance of ibandronic acid is low with average values in
the range of 84–160 mL/min. Renal clearance (about
60 mL/min in healthy postmenopausal females) accounts
for 50–60 % of total clearance and is related to creatinine
clearance. The difference between the apparent total and
renal clearances is considered to reflect the uptake by
bone [1, 2].
The present study aimed to compare the rate and extent
of absorption of ibandronate acid (as sodium ibandronate)
150 mg from a test medicinal product (test formulation;
Treatment A), manufactured by Tecnimede (Sintra, Por-
tugal) and that of the reference medicinal product (refer-
ence formulation; Treatment B; Bonviva), a surrogate for
therapeutic equivalence.
2 Volunteers and Methods
2.1 Study Protocol
The clinical study protocol and related documents were
approved by an independent ethics committee (Interna-
tional Review Board Services) and a No Objection Letter
(NOL) was obtained from Canadian authorities. The study
was conducted in accordance with the most recent version
of the Helsinki Declaration and Good Clinical Practice
Guideline [3]. Informed consent was obtained from partici-
pants prior to initiation of study procedures. The clinical and
analytical parts of the study were conducted at Inventive
Health’s facility (Que´bec City, QC, Canada). Pharmacoki-
netic and statistical analyses were also performed by Inven-
tive Health’s facility (Que´bec City, QC, Canada).
2.2 Volunteers
The 153 subjects were recruited from the community at
large and considered eligible for enrolment as per protocol
inclusion and exclusion criteria. Subjects included were
males or females of non-childbearing potential, nonsmok-
ers or moderate smokers (no more than nine cigarettes
daily), aged 18 years of age and older (C18 years) and
with body mass indices (BMI) greater than 18.5 kg/m2
([18.5) and less than 30.0 kg/m2 (\30.0). Females of non-
childbearing potential included post-menopausal females
or surgically sterile females. The screening procedures
included collection of anamnesis and demographic data
(gender, age, race, body weight [kg], height [cm] and
BMI), a physical examination, a resting 12-lead electro-
cardiogram (ECG), urine illicit drug screen, urine preg-
nancy test (female subjects) and clinical laboratory tests
(haematology, biochemistry, urinalysis, human immuno-
deficiency virus [HIV], hepatitis C [HCV] antibodies and
hepatitis B surface antigen [HBSAg]). The baseline
demographic characteristics of the pharmacokinetic popu-
lation are depicted in Table 1.
A total of 153 healthy subjects were randomly assigned to
a treatment in accordance with the computer-generated
blocks randomization scheme (block size 6, randomly vari-
able). The randomization scheme was generated using Sta-
tistical Analysis System (SAS) program version 9.2 (SAS
Institute Inc., Cary, NC, USA). This program used the ran-
domized block design to ensure an equal distribution of
sequences at multiples of 6 in the list of subject assignment.
Based on results of a previous pilot study, the within-
subject coefficients of variance (CVs) should be approxi-
mately 39 and 48 % for AUC and Cmax, respectively. Thus,
with these expected CVs and an expected ratio of AUC and
Cmax within 0.90 and 1.11, the study should have a power
of at least 90 % to show bioequivalence with 138 subjects.
In order to account for possible dropouts, 153 subjects were
included in the study.
2.3 Study Design
This study was a single-centre, randomized, single-dose,
open-label, three-way, three-sequence, reference




Height (cm) Weight (kg) BMI (kg/m2)
Mean ± SD 46 ± 13 170.0 ± 9.4 73.86 ± 10.38 25.50 ± 2.37
Range 18–73 146.0–195.0 49.00–106.10 19.55–29.70
Median 48 170.0 75.00 25.63
BMI body mass index, SD standard deviation
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formulation-replicated, crossover bioequivalence study to
compare the rate and extent of absorption of Tecnimede’s
test formulation of ibandronic acid (batch number 15044;
expiration date: 04-2013; manufactured by West Pharma,
SA, Portugal) with the reference formulation (batch num-
ber B1176B01; expiration date: 11-2015; manufactured by
Roche Pharma AG, Germany), acquired in the Polish
market, under fasting conditions, in healthy volunteers.
After an overnight fast of at least 10 hours, subjects
were dosed in the mornings. Subjects were administered
the test or the reference formulation, as per the randomi-
zation scheme, as a single oral dose of one film-coated
tablet containing 150 mg of study medication, with
240 mL of water. Subjects were dosed as specified in the
protocol, and subsequently fasted for a period of at least
4 hours. Subjects were served a controlled meal not less
than 4 hours post-dose, and at appropriate times thereafter,
in each period. Subjects were served standardized post-
dose meals similar in composition in each period. With the
exception of the volume administered at the time of dosing,
fluids were not permitted from 1 hour before dosing to
1 hour after dosing, but, after that period, plain water was
permitted ad libitum.
According with a reference formulation-replicated
design, the study had three periods (period 1, period 2 and
period 3) and the subjects were randomized to three
sequences (test-reference-reference [TRR]; reference-ref-
erence-test [RRT] and reference-test-reference [RTR]). In
each study period, subjects were administered the test
formulation (Treatment A) or the reference formulation
(Treatment B) as per the randomization scheme. The
treatment periods were separated by washout periods of
14 days.
The randomization scheme was kept unavailable to the
bioanalytical division until completion of the clinical and
analytical phases.
2.4 Drug Analysis
A dead-volume intravenous catheter was used for blood
collection, which occurred prior to drug administration and
0.167, 0.333, 0.500, 0.750, 1.00, 1.25, 1.50, 1.75, 2.00,
3.00, 4.00, 6.00, 8.00, 12.0, 24.0 and 48.0 hours post-dose
in each period. Actual sampling times were used in the
statistical analyses. Blood samples were cooled in an ice
bath and were centrifuged at 3,000 rpm (corresponding to
approximately 1,900 g) for at least 10 minutes at approx-
imately 4 C (no more than 110 minutes passed between
the time of each blood draw and the start of centrifugation).
The aliquots were transferred to a -20 C freezer, pending
transfer to the bioanalytical facility.
2.5 Pharmacokinetic Analysis
Pharmacokinetic analyses were performed using
Pharsight Knowledgebase ServerTM (version 4.0.2) and
WinNonlin (version 5.3), which are validated for bioe-
quivalence/bioavailability studies by Inventive Health.
Inferential statistical analyses were performed using SAS
(release 9.2) according to the Food and drug Administra-
tion (FDA), Health Product and Food Branch of Health
Canada and European Medicines Agency (EMA) guidance.
The number of observations (N), mean, standard devi-
ation (SD), CV%, range (minimum and maximum), median
and geometric mean were calculated for plasma concen-
trations of ibandronic acid for each sampling time and
treatment. These descriptive statistics were also presented
for the AUC from time zero to time of the last non-zero
concentration (AUC0–t), the AUC from time zero to infinity
(extrapolated) (AUC0–inf), the Cmax, the residual area cal-
culated through the equation (1 - AUC0–t/AUC0–inf) 9
100 %, time to Cmax (Tmax), the T el and the elimination
rate constant (Kel). The AUC0–t was calculated using the
Table 2 Pharmacokinetic variables for ibandronic acid for each treatment/period [mean ± SD and (CV%)]
Test formulation Bonviva (first administration) Bonviva (second administration)
N 146 146 142
AUC0–t (ngh/mL) 390.83 ± 287.27 (73.50) 388.54 ± 356.76 (91.82) 383.53 ± 246.72 (64.33)
AUC0–inf (ngh/mL) 404.49 ± 296.72 (73.36) 401.48 ± 366.54 (91.30) 397.65 ± 255.75 (64.31)
Residual area (%) 3.41 ± 0.84 (24.61) 3.30 ± 0.70 (21.03) 3.57 ± 0.95 (26.74)
Cmax (ng/mL) 96.71 ± 90.19 (93.25) 92.67 ± 91.48 (98.72) 87.94 ± 60.20 (68.46)
Tmax
a (h) 1.17 (0.333–8.00) 1.25 (0.333–4.00) 1.01 (0.333–8.02)
Kel (1/h) 0.0851 ± 0.0663 (77.89) 0.0847 ± 0.0679 (80.15) 0.0734 ± 0.0450 (61.32)
T el (h) 10.91 ± 4.25 (38.92) 10.76 ± 3.93 (36.51) 11.49 ± 3.90 (33.97)
a Median (min–max)
AUC0–inf area under the serum concentration–time curve from time zero to infinity AUC0–t area under the serum concentration–time curve from
time zero to time of last measurable concentration, Cmax maximum serum concentration, CV% coefficient of variance, Kel elimination rate
constant, N number of observations, SD standard deviation, T el elimination half-life, Tmax time to Cmax
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linear trapezoidal rule. AUC0–inf was calculated through
the following equation: AUC0–t ? (Ct/Kel), where Ct is the
fitted last non-zero concentration for that treatment.
2.6 Safety Analysis
Adverse events were listed and coded using Medical Dic-
tionary for Regulatory Activities (MedDRA), version
15.0. Treatment-emergent adverse events (TEAEs) were
summarized descriptively in the safety population, and
were tabulated by treatment group, system organ class,
preferred term, causality and severity.
2.7 Statistical Analysis
For the purpose of statistical analyses, the safety population
included the subjects who received at least one dose of the
investigational medicinal product whereas the pharmaco-
kinetic population included the subjects who completed at
least two periods including one period with test formula-
tion and other with the reference formulation and for whom
the pharmacokinetic profile was characterized. Pharmaco-
kinetic parameters were summarized by treatment. Plasma
concentrations were summarized by treatment and time-
point. Individual and mean plasma concentrations, as well
as the plots of the plasma levels for all subjects versus time,
were graphically displayed for three treatments.
Ln-transformed AUC0–t, AUC0–inf and Cmax were ana-
lysed using general linear model (GLM) procedure in
SAS following the method A recommended by the EMA
(CHMP Pharmacokinetics Working Party [PKWP] EMA/
618604/2008 Rev. 3). The statistical model included
sequence, period, treatment and subject within sequence as
fixed factors. The sequence effect was tested using the
subject-within-sequence effect as the error term. The
treatment and period effects were tested against the resid-
ual mean square error. Within-subject coefficient of vari-
ation (CVWR) was calculated for the reference product
using analysis of variance (ANOVA), on reference data
only, with sequence, subject within sequence, and period as
fixed effects. The point estimate and the 90 % geometric
confidence interval for the test-to-reference geometric
mean ratio (T/R) were calculated for AUC0–t, AUC0–inf and
Cmax using the least-squares means statement. Kel and T el
were also analysed using the GLM Procedure. Wilcoxon’s
test was performed on the mean Tmax for both treatments.
All statistical tests were performed at the alpha level of
0.05.
According to the regulatory requirements [4] translated
into the study protocol, the hypothesis of bioequivalence
between a generic medicinal product and a reference
medicinal product is accepted if the 90 % geometric con-
fidence intervals of the ratio of least-squares means of the
test to reference product of ln-transformed AUC0–t is
within the acceptance range of 80.00–125.00 %. For Cmax,
the protocol established a scaled average bioequivalence
approach. This approach is based on the CVWR: if the
CVWR is inferior or equal to 30 % (B30 %), the 90 %
geometric confidence intervals of the ratio T/R of least-
squares means of the ln-transformed Cmax should be within
the acceptable range of 80.00–125.00 % to conclude bio-
equivalence. On the other hand, if the CVWR for the ref-
erence product was superior to 30 % ([30 %) for Cmax, the
bioequivalence acceptance limits for this pharmacokinetic
parameter had to be scaled to the within-subject variability of
the reference product (to a maximum of 69.84–143.19 %).
For scaled average bioequivalence, the applicant should
justify that the calculated CVWR is a reliable estimate and
that it is not the result of outliers. Therefore, a box plot
analysis using the studentized intra-subject residuals from
the ANOVA model including only data for the reference
treatment was done using the univariate procedure in
SAS. A box plot was constructed from studentized intra-
subject residuals corresponding to the first administration
of reference product in each subject. Values that were
further away from the box by more than three interquartile
ranges were considered outlying observations and these
values are indicated by an asterisk in the box plot. The
detected outlying observations were excluded, and within
subject standard deviation of the log transformed parameter
(SWR) was re-estimated and used to widen bioequivalence




One hundred and fifty-three subjects (47 females and 106
males) were randomized to three sequences of treatment
(TRR, RTR and RRT), and received at least one dose of the
investigational medicinal products under study. This sam-
ple size was considered according to the protocol for safety
evaluation (safety population). Nevertheless, as previously
stated in the protocol, the subjects used for pharmacoki-
netic and statistical analysis, the pharmacokinetic popula-
tion, are those that completed at least two periods including
one test and one administration of the reference product
and for whom the pharmacokinetic profile was adequately
characterized (n = 146). One hundred and forty-two sub-
jects completed all study procedures. The disposition of
subjects is presented in Fig. 1.
After the test formulation (T) and first and second
Bonviva (R) dosing, the Cmax was 96.71 ± 90.19 ng/mL,
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92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the
AUC0–t was 390.83 ± 287.27 ngh/mL, 388.54 ± 356.76
ngh/mL and 383.53 ± 246.72 (64.33), respectively (Table 2).
No statistically significant difference between treatments was
detected using ANOVA for ln-transformed AUC0–t, AUC0–inf
and Cmax. A statistically significant period effect was detected
for AUC0–t and AUC0–inf (Table 3). The mean residual area
was less than 20 % for the AUCs obtained after administra-
tion of the test formulation (3.41 ± 0.84 %) as well as after
the first and second administrations of Bonviva (3.30 ± 0.70
and 3.57 ± 0.95 %, respectively). Mean concentration ver-
sus time curves were plotted and are presented in Fig. 2.
The CVWR for AUC0–t, AUC0–inf and Cmax were 39.77,
39.45 and 43.23 %, respectively. The limits of the accep-
tance range based upon the within-subject variability seen
in the bioequivalence study using scaled average bio-
equivalence were 73.01–136.97 %. No statistical outliers
were detected for the reference formulation following
examination of the distribution of the ln-transformed Cmax.
The 90 % confidence intervals were 95.05–110.67 for
Cmax, 94.35–107.94 for AUC0–t and 94.37–107.88 for
AUC0–inf, which are within the predefined bioequivalence
acceptance range of 80.00–125.00 %. For Cmax, the
observed ratio and confidence intervals were also within
Fig. 1 Disposition of subjects. A (Test) = Tecnimede—Sociedade Te´cnico—Medicinal S.A., Portugal, ibandronic acid 1 9 150-mg film-
coated tablet. B (Reference) = Roche Registration Limited, United Kingdom (Bonviva), ibandronic acid 1 9 150-mg film-coated tablet
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the limits of acceptance obtained using the scaled average
bioequivalence approach. Wilcoxon’s test performed on
the tmax data showed no statistically significant difference
between treatments (p = 0.1382).
The least-squares means ratios, the 90 % geometric
confidence intervals, and the CVWR for the reference
product are presented in Table 4.
3.2 Safety Analysis
A total of 279 TEAEs were reported by 91 of the 153
subjects who received at least one dose of the medicinal
product (safety population): 96 TEAEs were reported by
28.8 % (42/146) of the subjects when they received the test
medicinal product (Treatment A) and 183 TEAEs were
reported by 47.7 % (73/153) of the 153 subjects when they
received the reference medicinal product (Treatment B).
Myalgia was reported by 38 subjects, diarrhoea by 22
subjects and abdominal pain by 16 subjects, corresponding
to 24.8, 17.6 and 10.5 % of the safety population
(n = 153), respectively. After the causality assessment of
the 279 TEAEs, 70 were judged as ‘probable/likely’, 176
as ‘possible’ and 33 as ‘unlikely’.
When comparing the number of subjects for each
MedDRA preferred term, there are no relevant differ-
ences between treatments with the exception of the head-
ache and myalgia TEAEs, which were reported by 11 and
19 subjects, respectively, after the administration of
Treatment A and by 21 and 29 subjects, respectively, after
Fig. 2 Mean plasma ibandronic
acid concentrations obtained for
the test and reference
formulations following a
150-mg dose (log scale).
N = 146 for ibandronic acid,
N = 146 for Bonviva (first




Table 3 p Values for treatment, period and sequence effects for the
pharmacokinetic variables of ibandronic acid
p Values
Treatment Period Sequence
AUC0–t 0.8227 0.0127 0.9091
AUC0–inf 0.8255 0.0099 0.9010
Cmax 0.5835 0.1291 0.8606
AUC0–inf area under the serum concentration–time curve from time
zero to infinity AUC0–t area under the serum concentration–time curve
from time zero to time of last measurable concentration, Cmax max-
imum serum concentration
Table 4 Ibandronic acid: ratios, 90 % geometric confidence intervals (CI) for AUC0–t, AUC0–inf and Cmax and intra-subject CV for Bonviva

Variable Treatment comparisons Ratioa (%) 90 % CIb (%) Intra-subject CV (Bonviva) (%)
AUC0–t Test (A)—reference (B) 100.92 94.35–107.94 39.77
AUC0–inf Test (A)—reference (B) 100.90 94.37–107.88 39.45
Cmax
c Test (A)—reference (B) 102.56 95.05–110.67 43.23
a Calculated using least-squares means
b 90 % geometric confidence interval using ln-transformed data
c The scaled average bioequivalence approach was used for Cmax and the widened limits obtained were 73.01–136.97 %
AUC0–inf area under the serum concentration–time curve from time zero to infinity AUC0–t area under the serum concentration–time curve from
time zero to time of last measurable concentration, Cmax maximum serum concentration, CV coefficient of variance
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the administration of Treatment B. The severity of each
TEAE was graded as mild (n = 223), moderate (n = 50)
or severe (n = 6). No serious adverse event was reported in
this study.
4 Discussion and Conclusions
Ibandronic acid is a bisphosphonate compound indicated
for the treatment and prevention of osteoporosis in post-
menopausal women and the reduction of skeletal compli-
cations of malignant disease. The absorption in the upper
gastrointestinal tract is rapid after oral administration with
an absolute bioavailability of about 0.6 %.
A generic medicinal product is considered to be bio-
equivalent to a reference medicinal product when the 90 %
confidence interval around the estimated ratio of geometric
means of AUC and Cmax is between 0.80 and 1.25 [4]. As
per regulatory and scientific requirements, when a generic
medicinal product and a reference medicinal product are
compared, a single-dose, crossover design is recommended
[4].
In studies with crossover design, the amplitude of the
confidence interval is proportional to the within-subject SD
of the pharmacokinetic parameter and reciprocally pro-
portional to the square-root of the number of subjects [5].
Consequently, the regulatory bioequivalence limits of 0.80
and 1.25 are frequently penetrated when the intra-individ-
ual variation is high unless the number of subjects is also
large.
Ibandronic acid is a highly variable drug and, although
the reference literature confirms acceptance of widening of
confidence intervals in Europe, based on non-replicate
designs [2], the latest update in the bioequivalence guide-
line requires that, in order to widen the intervals for Cmax, a
replicate design must be used. Besides the fact of allowing
for the widening of the intervals for Cmax, replicate designs
possess the advantage of reducing the sample size of sub-
jects required to demonstrate bioequivalence between the
two formulations.
However, one of the main issues with a replicate design
is the increased duration of the clinical phase of the study,
since a full replicate study with four periods will require
three washout intervals and a partial replicate with three
periods will require two washout intervals. This represents
more than three or two times, respectively, the required
amount of time to conduct a simple crossover study.
Therefore, by increasing the duration of the study and the
number of dosing periods, replicate designs normally
exhibit a higher dropout rate, which impacts negatively on
the required sample size.
The issue with the higher dropout rates is evident by
analysing the bibliographic references, which shows 15.8
and 12.5 % dropout rates for full replicate studies [6, 7],
while, according to our experience, we achieved a dropout
rate of 7.2 % for this partial replicate study and a 4.2 %
dropout rate in a pilot crossover study (data on file).
So, in trying to achieve a compromise between an
extended duration of the clinical phase and reducing the
sample size without much impact from the dropout rate, we
decided to conduct this study as a partial replicate design
with three periods, including two administrations of the
reference formulation in each sequence. This turned out to
be a favourable decision since, according to the guidelines
[4], the replicate design allowed for the scaled bioequiva-
lence approach for Cmax and the duration of the clinical
phase was contained and acceptable (37 days as opposed to
the required 54 days in a four-period full replicate design),
which led to a dropout rate lower than the one observed for
full replicate studies. Further to this, the results of the study
demonstrated that the within-subject variability for Cmax of
the reference formulation was more than 30 % and this
value was not the result of the presence of outliers.
However, it is important to point out that a replicate
design may not be the solution if high within-subject var-
iability is observed for the AUC parameter, which was not
the case for ibandronic acid, since the bioequivalence
guideline does not allow for the widening of intervals for
that pharmacokinetic parameter [4].
The treatment periods should be separated by a washout
period of at least five T el in order to guarantee that the
drug concentrations are below the lower limit of quantifi-
cation at the beginning of each period [4]. In this study, the
treatment periods were separated by a washout of 14 days.
When reviewing the published data on ibandronic acid
pharmacokinetic properties, the authors noticed that the
published half-life of ibandronic acid ranges from 10 to
60 hours [1] and, in one study in postmenopausal women
that received a single oral dose of ibandronic acid150 mg,
a mean T el of 72 hours was observed [8]. In the current
study, the T el of ibandronic acid was approximately
10 hours for both formulations, which is in line with
published studies but also in the lower limit of the range of
values published. This may be explained by the fact that
the participants in the study were healthy volunteers since
similar half-life values were observed in phase I pharma-
cokinetic studies with the reference product in healthy
subjects.
The mean residual area was less than 20 % for all
treatments indicating that a sampling over a period of
48 hours was sufficient.
A statistically significant period effect was detected for
AUCs. A statistically significant period effect could be an
indication of an equal carryover effect. However, since
there was no detectable pre-dose concentration at any of
the study periods and there was no sequence effect, there is
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no indication of carryover effect. As the intra-subject
variability was smaller for the AUCs as compared with
Cmax, the power of the study was higher for these param-
eters. Consequently, small differences between periods
could be detected which should not be clinically
meaningful.
In this bioequivalence study, all the ratios and 90 %
geometric confidence intervals were within the acceptance
ranges. The conventional acceptance range of 0.80 and
1.25 was even met for Cmax (Table 4). Based on these
results, it can be concluded that the test formulation of
ibandronic acid is bioequivalent to the test reference
Bonviva following a 1 9 150-mg dose under fasting
conditions.
The number of subjects reporting TEAE and the number
of TEAE reported after intake of reference medicinal
product (Treatment B—Bonviva) is higher than the
number of subjects reporting TEAE and the number of
TEAE reported following intake of the test medicinal
product (Treatment A—test formulation). These differ-
ences between treatments can be explained by study
design, a reference-replicate crossover study, since all
subjects who completed the study received two doses of the
reference medicinal product and only one dose of the test
medicinal product.
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